Smitha Mruthyunjayappa
Overview
Explore the profile of Smitha Mruthyunjayappa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mruthyunjayappa S, Patel C, Reddy S, Al Diffalha S
BMJ Case Rep
. 2022 Jul;
15(7).
PMID: 35858746
Herein, we report a man in his 70s with gallbladder mass. Microscopically, the tumour demonstrated moderately differentiated adenocarcinoma, sarcoma with focal chondroid differentiation and high-grade neuroendocrine tumour component arising in...
2.
Hardie A, Chamberlin J, Boyum J, Sharbidre K, Petrocelli R, Flemming B, et al.
Acad Radiol
. 2021 Oct;
29(8):1149-1156.
PMID: 34598868
Rationale And Objectives: To date, no clinically useful classification system has been developed for reliably differentiating mucinous cystic neoplasm (MCN) from a benign hepatic cyst (BHC) in the liver. The...
3.
Aye J, Stafman L, Williams A, Garner E, Stewart J, Anderson J, et al.
Oncotarget
. 2019 Oct;
10(53):5534-5548.
PMID: 31565187
Aggressive therapies for patients with metastatic Wilms tumor (WT) with subsequent severe late effects warrant the search for novel therapies. The role of focal adhesion kinase (FAK), a non-receptor tyrosine...
4.
Mruthyunjayappa S, Zhang K, Zhang L, Eltoum I, Siegal G, Wei S
Hum Pathol
. 2019 Jul;
92:1-9.
PMID: 31351153
The incidence of bilateral breast cancer (BBC) reportedly ranges from 1.4 to 11.8%. Women with a first primary breast cancer are at a 2- to 6-fold increased risk of developing...
5.
Stafman L, Mruthyunjayappa S, Waters A, Garner E, Aye J, Stewart J, et al.
Oncotarget
. 2018 Jun;
9(32):22665-22679.
PMID: 29854306
Increasing incidence coupled with poor prognosis and treatments that are virtually unchanged over the past 20 years have made the need for the development of novel therapeutics for hepatoblastoma imperative....
6.
Waters A, Stafman L, Garner E, Mruthyunjayappa S, Stewart J, Friedman G, et al.
Transl Oncol
. 2016 Oct;
9(5):419-430.
PMID: 27751346
Rhabdomyosarcoma (RMS), a tumor of skeletal muscle origin, is the most common sarcoma of childhood. Despite multidrug chemotherapy regimens, surgical intervention, and radiation treatment, outcomes remain poor, especially in advanced...
7.
Waters A, Stafman L, Garner E, Mruthyunjayappa S, Stewart J, Mroczek-Musulman E, et al.
Transl Oncol
. 2016 Aug;
9(4):263-73.
PMID: 27567948
Despite the tremendous advances in the treatment of childhood solid tumors, rhabdomyosarcoma (RMS) continues to provide a therapeutic challenge. Children with metastatic or relapsed disease have a disease-free survival rate...